SCHEMBL1992318

SCHEMBL1992318

O=C1NC(=O)C(c2cn(C3CCN4CCNCC4C3)c3ccccc23)=C1c1c[nH]c2sccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 13/20 0.51
PRKCB P05771 13/20 0.51
PRKCG P05129 12/20 0.51
PRKCA P17252 12/20 0.51
PRKCE Q02156 12/20 0.51
PRKCD Q05655 11/20 0.51
PRKCH P24723 10/20 0.51
CAMK2B Q13554 8/20 0.51
CAMK2G Q13555 8/20 0.51
CAMK2A Q9UQM7 8/20 0.51
PRKCZ Q05513 7/20 0.51
SRC P12931 3/20 0.51
PRKACA P17612 5/20 0.40
PRKACB P22694 5/20 0.40
PRKACG P22612 4/20 0.40
GSK3B P49841 4/20 0.40
CDK2 P24941 2/20 0.40
GSK3A P49840 2/20 0.40
PIP5K1C O60331 1/20 0.40
RPS6KA5 O75582 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997401 0.88 CAMK2D (0.53) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1991052 0.87 PRKCB (0.58) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1999506 0.87 PRKCG (0.51) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1995932 0.85 PRKCA (0.37) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1990883 0.80 CAMK2D (0.59) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1993777 0.78 CAMK2D (0.55) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1992365 0.78 CAMK2D (0.55) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1993242 0.78 PRKCH (0.45) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1993731 0.77 CAMK2D (0.58) CAMK2DPRKCBPRKCGPRKCAPRKCE
SCHEMBL1996284 0.77 PRKCA (0.58) CAMK2DPRKCBPRKCGPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO CAMK2D 2963/4885PRKCB 3335/4885PRKCG 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.